We are live on ! Find out more
AZN icon

AstraZeneca

544 hedge funds and large institutions have $17.3B invested in AstraZeneca in 2018 Q3 according to their latest regulatory filings, with 65 funds opening new positions, 151 increasing their positions, 197 reducing their positions, and 47 closing their positions.

New
Increased
Maintained
Reduced
Closed

207% more call options, than puts

Call options by funds: $225M | Put options by funds: $73.5M

38% more first-time investments, than exits

New positions opened: 65 | Existing positions closed: 47

23% more capital invested

Capital invested by funds: $14B → $17.3B (+$3.3B)

3% more funds holding

Funds holding: 530544 (+14)

1.19% more ownership

Funds ownership: 16.09%17.28% (+1.2%)

23% less repeat investments, than reductions

Existing positions increased: 151 | Existing positions reduced: 197

40% less funds holding in top 10

Funds holding in top 10: 53 (-2)

Holders
544
Holders Change
+14
Holders Change %
+2.64%
% of All Funds
12.44%
Holding in Top 10
3
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-40%
% of All Funds
0.07%
New
65
Increased
151
Reduced
197
Closed
47
Calls
$225M
Puts
$73.5M
Net Calls
+$152M
Net Calls Change
+$45M
Name Holding Trade Value Shares
Change
Change in
Stake
TRCT
351
Tower Research Capital (TRC)
New York
$251K +$224K +2,966 +1,399%
V
352
Veritable
Delaware
$246K -$64.1K -848 -21%
CIC
353
Carnegie Investment Counsel
Ohio
$244K +$226K +2,986 New
AssetMark Inc
354
AssetMark Inc
California
$243K -$11.3K -150 -5%
ASN
355
Advisory Services Network
Georgia
$241K -$18.1K -239 -7%
HI
356
Hudock Inc
Pennsylvania
$241K +$151 +2 +0.1%
CGL
357
Clarius Group LLC
Washington
$240K
VF
358
Virtu Financial
New York
$238K -$948K -12,530 -81%
NERM
359
New England Research & Management
Illinois
$238K
SC
360
Saturna Capital
Washington
$237K
PCG
361
Private Capital Group
Connecticut
$236K -$17.5K -231 -7%
MA
362
MUFG Americas
New York
$235K
AWM
363
Altium Wealth Management
New York
$233K -$53.9K -712 -19%
CYG
364
Clean Yield Group
Vermont
$233K +$223K +2,950 New
GHAM
365
Gilman Hill Asset Management
Connecticut
$231K
NCM
366
Neumann Capital Management
California
$231K
UCMOK
367
United Capital Management of KS
Kansas
$231K +$234K +3,093 New
LCM
368
Laurion Capital Management
New York
$226K +$216K +2,850 New
DP
369
Dearborn Partners
Illinois
$226K +$216K +2,857 New
CHP
370
Cable Hill Partners
Oregon
$224K -$1.66K -22 -0.8%
Two Sigma Investments
371
Two Sigma Investments
New York
$223K -$4.6M -60,764 -96%
GA
372
GFS Advisors
Texas
$222K -$321K -4,250 -60%
TPWA
373
TRUE Private Wealth Advisors
Oregon
$220K -$69.4K -917 -25%
BIM
374
Baldwin Investment Management
Pennsylvania
$218K +$208K +2,750 New
Wolverine Trading
375
Wolverine Trading
Illinois
$216K -$584K -7,716 -74%

AZN Hedge Fund Activity: Q3 2018 in Review

544 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in AstraZeneca (AZN) for Q3 2018, worth a combined $17.3B — up 23% from $14B a quarter earlier.

Buyers outnumbered sellers: 65 funds opened new AZN positions and 47 closed out — a net gain of 18 holders — while 151 added to existing stakes and 197 trimmed.

The largest buyer was Jennison Associates, adding an estimated $774M. The largest seller was Bank of America, cutting an estimated $123M.

  • 544 institutional investors held AstraZeneca (AZN) as of Q3 2018, up from 530 in Q2 2018.
  • Funds reported $17.3B of AstraZeneca stock for Q3 2018, up 23% quarter-over-quarter.
  • 65 funds opened new AstraZeneca positions in Q3 2018 and 47 closed out, a net change of +18 holders.
  • The largest AstraZeneca buyer in Q3 2018 was Jennison Associates, an estimated $774M added.
  • The largest AstraZeneca seller in Q3 2018 was Bank of America, an estimated $123M sold.

Based on aggregated 13F filings for Q3 2018.